Pull to refresh
Logo
What Changed
Following Why Sign Up
Gene therapy options for Duchenne muscular dystrophy

Gene therapy options for Duchenne muscular dystrophy

New Capabilities

Regenxbio has finished dosing and plans to file for FDA approval in the third quarter of 2026

October 26th, 2026: Cell publishes in vivo genome-editing Duchenne study

Overview

Updated Nov 1

Regenxbio's RGX-202 met the main goal of its AFFINITY DUCHENNE trial in May 2026. In 93% of treated boys with usable biopsies, muscle made microdystrophin, a shortened form of the missing protein, at more than 10% of normal levels by week 12. The company finished dosing a confirmatory study and plans to file for FDA approval in the third quarter of 2026.

Two serious side effects appeared, heart inflammation in an 8-year-old and a symptomless liver injury in a 10-year-old, and both resolved without lasting harm. Nine boys have one-year movement data, and they scored better than untreated comparison groups on the North Star Ambulatory Assessment and timed tests. Approval could come in the second half of 2027.

Why it matters

Roughly 12,000 American boys have Duchenne; a second gene therapy doubles their treatment options after safety questions emerged about the first.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

10,000–15,000
U.S. patients with Duchenne
Almost all are boys; most are diagnosed before age 5.
$3.2M
Elevidys list price
Per-patient cost of Sarepta's one-time gene therapy, billed in a single dose.
2
Gene therapy contenders
Sarepta's approved Elevidys plus Regenxbio's RGX-202, which is heading for an FDA filing.
93%
Boys hitting the protein target
Share of RGX-202 participants with usable biopsies who made microdystrophin above 10% of normal at week 12.
Mid-20s
Typical age of death
Without an effective treatment, Duchenne is fatal in early adulthood from heart and lung failure.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

CS
Curran Simpson
Chief executive, Regenxbio
Preparing RGX-202 biologics license application for the third quarter of 2026
DI
Doug Ingram
Chief executive, Sarepta Therapeutics
Defending Elevidys against safety questions and new competition

Organizations Involved

Regenxbio
Regenxbio
Biotechnology company
Completed dosing in confirmatory RGX-202 study; BLA planned for Q3 2026

Rockville, Maryland biotech that spun out of University of Pennsylvania gene therapy research and licenses its NAV adeno-associated virus (AAV) vector platform to other drugmakers.
Sarepta Therapeutics
Sarepta Therapeutics
Biotechnology company
Marketing Elevidys under restricted label

Cambridge, Massachusetts biotech that built its business around Duchenne treatments, including three exon-skipping drugs and the gene therapy Elevidys.
FDA Center for Biologics Evaluation and Research
FDA Center for Biologics Evaluation and Research
Federal regulatory agency division
Reviewing gene therapy approvals and safety

The U.S. Food and Drug Administration unit that reviews gene therapies, vaccines, and other biologic drugs.

Timeline

1986 October 2026

11 events Latest: October 26th, 2026 · 2 weeks ago Showing 8 of 11
Tap a bar to jump to that date

  1. Cell publishes in vivo genome-editing Duchenne study

    Latest Science

    A Cell paper reports preclinical work and a first-in-human trial of an in vivo genome-editing therapy for Duchenne, a different approach from the virus-delivered gene therapies Regenxbio and Sarepta are developing.

  2. FDA places clinical hold on Regenxbio's Hunter syndrome therapy

    Regulatory

    The FDA halts the RGX-121 program for Hunter syndrome after asymptomatic spine MRI findings in five participants. Regenxbio says it no longer expects to resubmit the application soon and remains focused on its Duchenne filing.

  3. FDA panel reviews Capricor's Duchenne cell therapy

    Regulatory

    The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee meets to review Capricor's deramiocel, a cell therapy for Duchenne heart complications. FDA staff had said the Phase 3 HOPE-3 trial did not clearly show the drug works.

  4. Confirmatory RGX-202 study finishes enrollment

    Clinical Trial

    Regenxbio completes enrollment in the confirmatory study of RGX-202, part of a program that will supply a safety dataset of 63 patients for the FDA filing.

  5. Regenxbio gene therapy clears pivotal trial

    Clinical Trial

    Regenxbio says RGX-202 met the primary endpoint of the AFFINITY DUCHENNE trial: 93% of treated boys with usable biopsies made microdystrophin above 10% of normal at week 12, with average expression of 71.1%.

  6. FDA's top gene therapy regulator resigns

    Personnel

    Peter Marks, the CBER director who approved Elevidys, resigns over policy disputes with the Department of Health and Human Services.

  7. Elevidys linked to patient deaths

    Safety

    Sarepta reports deaths from acute liver failure in non-ambulatory teens treated with Elevidys and voluntarily pauses dosing in that group.

  8. FDA expands Elevidys to all ages

    Regulatory

    FDA broadens the Elevidys label to cover ambulatory and non-ambulatory patients regardless of age, opening the drug to thousands more boys.

  9. Elevidys becomes first Duchenne gene therapy

    Regulatory

    FDA grants accelerated approval to Sarepta's Elevidys for ambulatory boys ages 4-5. List price: $3.2 million per one-time infusion.

  10. First Duchenne drug approved

    Regulatory

    FDA grants accelerated approval to Sarepta's Exondys 51, an exon-skipping drug, over the objections of agency reviewers who cited weak efficacy data.

  11. Dystrophin gene identified

    Science

    Researchers at Harvard pinpoint the gene that, when mutated, causes Duchenne. The discovery sets the target for every future Duchenne therapy.

Scenarios

1

FDA approves Regenxbio's gene therapy

Likely Resolves by End of 2027

Discussed by: STAT News, biotech analysts at Evercore ISI and Stifel

Regenxbio submits a biologics license application by late 2026, FDA grants priority review, and approval follows in 2027. The company launches at a list price near Elevidys and competes for new patients and switches. This is the base case given the pivotal trial success and FDA's willingness to approve Duchenne therapies on accelerated pathways.

2

Safety signal emerges in Regenxbio follow-up

Possible Resolves by Q2 2027

Discussed by: Duchenne family advocates, FDA gene therapy review staff

Adeno-associated virus gene therapies, including Elevidys and Zolgensma, have shown immune and liver toxicity. As Regenxbio dosed more patients and follow-up extended, a serious adverse event or death surfaces, forcing a trial pause or label restriction at submission. This would slow approval or narrow the eligible population.

3

Sarepta's Elevidys label further restricted

Possible Resolves by May 14, 2027

Discussed by: FDA reviewers, Sarepta investors, Duchenne patient organizations

With a viable second option in sight, FDA tightens Elevidys eligibility further, narrows the label to ambulatory boys only, or requires new safety studies. Sarepta could also withdraw the drug from non-ambulatory patients entirely. The agency has been more willing to act on safety since Peter Marks resigned in 2025.

4

FDA approves Capricor's deramiocel for Duchenne heart damage

Uncertain Resolves by Q2 2027

Discussed by: FDA staff reviewers, Endpoints News

Capricor's cell therapy wins approval for the heart complications of Duchenne despite an FDA briefing document that questioned whether the Phase 3 HOPE-3 trial showed the drug works. The FDA's decision was due by August 22, 2026. Approval would add a non-gene therapy option to the Duchenne market.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

May 2019

Zolgensma approval for spinal muscular atrophy (2019)

FDA approved Novartis's Zolgensma, a one-time AAV gene therapy for spinal muscular atrophy in children under 2. At $2.1 million, it was the most expensive drug ever approved at the time. It used an AAV9 vector built on the Regenxbio NAV platform under license.

Then

Zolgensma joined Biogen's earlier antisense drug Spinraza, giving SMA families two treatment options where they had none in 2015.

Now

Roche's Evrysdi followed in 2020, and SMA shifted from a near-certain infant fatality to a manageable condition for many patients.

Why this matters now

The same script may now play out for Duchenne. A second gene therapy arrives a few years after the first, giving doctors a choice and pressuring the incumbent on price and safety.

December 2013 to 2017

Hepatitis C drug competition (2014-2017)

Gilead's Sovaldi launched in 2013 as a near-cure for hepatitis C, priced at $1,000 per pill or $84,000 per course. AbbVie's Viekira Pak launched the next year, followed by Gilead's own Harvoni and later Mavyret. Insurers and pharmacy benefit managers used the second entrant to negotiate steep rebates.

Then

Net prices fell more than 50% within three years of the first competitor launch.

Now

Hepatitis C cure rates climbed past 95% in treated patients, and the U.S. cleared most of its diagnosed backlog by the early 2020s.

Why this matters now

Drug competition routinely lowers prices and broadens access. A second approved Duchenne gene therapy gives insurers and Medicaid programs leverage that did not exist with one supplier.

June 2023

Elevidys accelerated approval debate (2023)

FDA's CBER division, then run by Peter Marks, approved Elevidys despite a divided advisory committee vote and objections from agency reviewers who said the efficacy data was thin. The approval was conditional, requiring a confirmatory trial.

Then

Sarepta launched at $3.2 million per dose, the highest list price ever for an FDA-approved drug at the time of approval.

Now

When Elevidys was later linked to patient deaths, the original approval decision came under renewed scrutiny and contributed to Marks's resignation in March 2025.

Why this matters now

Regenxbio's submission lands in a more skeptical FDA. Reviewers will weigh safety more heavily than they did three years ago, and the bar for accelerated approval may be higher.

Sources

(8)
+2
STAT News Regenxbio Regenxbio FDA Endpoints News Cell Regenxbio Regenxbio